[go: up one dir, main page]

SG11201809780WA - Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same - Google Patents

Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Info

Publication number
SG11201809780WA
SG11201809780WA SG11201809780WA SG11201809780WA SG11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA
Authority
SG
Singapore
Prior art keywords
international
methods
ebolavirus
nucleic acid
disclosed
Prior art date
Application number
SG11201809780WA
Inventor
David Weiner
Ami Patel
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of SG11201809780WA publication Critical patent/SG11201809780WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property --11` . 1#1101111 0 11101 HOE 010 1111 1 0 I 11E1 OH MO 1110111111110 ill 011 1111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......\"' WO 2017/192947 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: NGUYEN, Quang, D. et al.; Riverside Law, LLP, A61K 35/76 (2015.01) A61P 31/14 (2006.01) Glenhardie Corporate Center, 1285 Drummers Lane, Suite A61K 39/12 (2006.01) A61P 37/04 (2006.01) 202, Wayne, PA 19087 (US). A61K 48/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/031215 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 05 May 2017 (05.05.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (25) Filing Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 62/332,372 05 May 2016 (05.05.2016) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/402,519 30 September 2016 (30.09.2016) US (84) Designated States (unless otherwise indicated, for every 62/483,979 11 April 2017 (11.04.2017) US kind of regional protection available): ARIPO (BW, GH, (71) Applicant: WEINER, David [US/US]; 717 Beacom Lane, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Merion, PA 19066 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventors; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicants: PATEL, Ami [US/US]; 1 Rainey Court, — ou MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = Philadelphia, PA 19103 (US). YAN, Man [US/US]; 503 Sh- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, effield Drive, Wallingford, PA 19086 (US). KM, ML, MR, NE, SN, TD, TG). = (54) Title: FILOVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCIENS MADE THEREFROM, AND METHODS OF USING SAME = = Q. Durba (05DRC99) '99 '07 Uganda (01Liga07) = '99 Durba (07DRC99) = Ozolin 75 Musoke '80 '67 Popp = E Leiden '08 = = '05 Angola R'jn Du 8 rba 7 1 (09ORC99) 99 _ ----t C = 0.005 Uganda (02ltga07) '07 = '96 Booun Mayibout '96 '94 Mekouka r'—' Bonifaee '76 Kikwit 95 '— Maleo '79 ZEf3OV CON VACCINE SLIDV CON VACCINE _ '76 Yambuku (Ekron) '--- Yambick '04 11 '00 Yambuku (Mayinga) 76 Gun] Kasai 'DS .. 0_005 ' Kasai '07 1.--' '05 Eteumbi '03 11' Mbomo/Mbandza 0.005 ei cT 1-1 ----- (57) : Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus ,-1 Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that 0 encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. \" Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus C: proteins are disclosed. [Continued on next page] WO 2017/192947 Al MIDEDIMOMMIDIRMEMOMOIHMENHOHMEMOIMIE Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
SG11201809780WA 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same SG11201809780WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662332372P 2016-05-05 2016-05-05
US201662402519P 2016-09-30 2016-09-30
US201762483979P 2017-04-11 2017-04-11
PCT/US2017/031215 WO2017192947A1 (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Publications (1)

Publication Number Publication Date
SG11201809780WA true SG11201809780WA (en) 2018-12-28

Family

ID=60203604

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202011017RA SG10202011017RA (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
SG11201809780WA SG11201809780WA (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202011017RA SG10202011017RA (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Country Status (11)

Country Link
US (2) US11091518B2 (en)
EP (1) EP3452068A4 (en)
JP (3) JP7029756B2 (en)
KR (2) KR20240099514A (en)
CN (2) CN110072536B (en)
AU (2) AU2017261306B2 (en)
BR (1) BR112018072719A2 (en)
CA (1) CA3023098A1 (en)
MX (2) MX2018013524A (en)
SG (2) SG10202011017RA (en)
WO (1) WO2017192947A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072536B (en) * 2016-05-05 2024-02-02 宾夕法尼亚大学理事会 Filovirus consensus antigens, nucleic acid constructs, vaccines made therefrom, and methods of use thereof
EP3548054A4 (en) * 2016-12-02 2020-12-02 The Trustees of the University of Pennsylvania DNA ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS
CN110655572B (en) * 2019-10-11 2022-08-16 中国科学院广州生物医药与健康研究院 Monoclonal antibody for resisting filovirus GP protein and application thereof
WO2024233996A2 (en) * 2023-05-11 2024-11-14 The Wistar Institute Of Anatomy And Biology Vaccines against african swine fever virus, and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR20240010758A (en) * 2012-04-12 2024-01-24 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
ES2817903T3 (en) * 2013-03-15 2021-04-08 Univ Pennsylvania Consensus proteins of the foot-and-mouth disease virus (AFV), coding sequences and vaccines prepared from them
HRP20240163T1 (en) * 2014-09-03 2024-04-12 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
WO2016054003A1 (en) * 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
CN110072536B (en) * 2016-05-05 2024-02-02 宾夕法尼亚大学理事会 Filovirus consensus antigens, nucleic acid constructs, vaccines made therefrom, and methods of use thereof

Also Published As

Publication number Publication date
CN117887735A (en) 2024-04-16
KR20190037200A (en) 2019-04-05
CN110072536A (en) 2019-07-30
SG10202011017RA (en) 2020-12-30
JP7584770B2 (en) 2024-11-18
EP3452068A4 (en) 2020-01-22
AU2024203524A1 (en) 2024-06-20
AU2017261306A1 (en) 2018-12-20
US11091518B2 (en) 2021-08-17
US20210388033A1 (en) 2021-12-16
BR112018072719A2 (en) 2019-02-19
CA3023098A1 (en) 2017-11-09
EP3452068A1 (en) 2019-03-13
AU2017261306B2 (en) 2024-02-29
JP2022078067A (en) 2022-05-24
MX2018013524A (en) 2019-06-10
WO2017192947A1 (en) 2017-11-09
US20190153040A1 (en) 2019-05-23
JP2025017370A (en) 2025-02-05
KR20240099514A (en) 2024-06-28
KR102678400B1 (en) 2024-06-26
CN110072536B (en) 2024-02-02
JP2019516400A (en) 2019-06-20
MX2023003934A (en) 2023-04-26
US12240872B2 (en) 2025-03-04
JP7029756B2 (en) 2022-03-04

Similar Documents

Publication Publication Date Title
SG11201811432WA (en) Rna for cancer therapy
SG11201806340YA (en) Zika virus vaccine
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201909927RA (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
SG11201808152PA (en) Dna antibody constructs and method of using same
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201903042VA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201809684YA (en) Adeno-associated virus variant capsids and methods of use thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201408459VA (en) Purification of virus like particles
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201804713VA (en) TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
SG11201805229YA (en) Means and methods for treating hbv
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201809780WA (en) Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same